Earnings Summary

Atara Biotherapeutics Inc’s revenue fell -98.14% since last year same period to $0.96Mn in the Q2 2023. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 179.82% jump in its revenue since last 3-months.

Atara Biotherapeutics Inc’s net profit fell -485.08% since last year same period to $-71.11Mn in the Q2 2023. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 4.9% jump in its net profits since last 3-months.

Atara Biotherapeutics Inc’s net profit margin fell -20854.23% since last year same period to -7430.3% in the Q2 2023. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 66.01% jump in its net profit margins since last 3-months.

Atara Biotherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.51 - a 34.62% jump from last quarter’s estimates.

Atara Biotherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.51.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Atara Biotherapeutics Inc’s return on assets (ROA) stands at -0.55.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Atara Biotherapeutics Inc’s return on equity (ROE) stands at -2.3.